Pavurutamab

Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA) . Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798) . The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) [1][2][3][4].

Product Specifications

CAS Number

[2250292-39-6]

Product Name Alternative

AMG-701

UNSPSC

12352203

Target

CD3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pavurutamab.html

Purity

99.9

Solubility

10 mM in DMSO

Smiles

[Pavurutamab]

Molecular Weight

(105.78 kDa)

References & Citations

[1]Sheridan C. Bispecific antibodies poised to deliver wave of cancer therapies. Nat Biotechnol. 2021 Mar;39 (3) :251-254. |[2]Goldsmith SR, et al. Bispecific Antibodies for the Treatment of Multiple Myeloma. Curr Hematol Malig Rep. 2022 Dec;17 (6) :286-297. |[3]Cho SF, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020 Sep 8;4 (17) :4195-4207. |[4]Harrison S J, et al. A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE® (bispecific T-cell engager) molecule, in relapsed/refractory (RR) multiple myeloma (MM) [J]. Blood, 2020, 136: 28-29.|[5]Goldstein RL, et al. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv. 2020 Sep 8;4 (17) :4180-4194.